Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer

被引:14
|
作者
Dang, Yutao [1 ,2 ]
Wang, Ruotian [1 ]
Qian, Kun [1 ]
Lu, Jie [3 ]
Zhang, Haixiang [4 ]
Zhang, Yi [1 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, Beijing, Peoples R China
[2] Capital Med Univ, Shijingshan Hosp Beijing City, Dept Thorac Surg, Shijingshan Teaching Hosp, Beijing, Peoples R China
[3] Capital Med Univ, Xuanwu Hosp, Dept Radiol, Beijing, Peoples R China
[4] Tianjin Univ, Ctr Appl Math, Tianjin, Peoples R China
来源
关键词
epidermal growth factor receptor mutation; nomogram; non‐ small‐ cell lung cancer; prediction model; radiomics; KRAS GENE-MUTATIONS; EGFR MUTATION; HISTOLOGIC-SUBTYPES; INTRATUMOR HETEROGENEITY; TEXTURE ANALYSIS; ADENOCARCINOMA; FEATURES; ASSOCIATION; SMOKERS; CLASSIFICATION;
D O I
10.1002/acm2.13107
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To determine the prognostic factors of epidermal growth factor receptor (EGFR) mutation status in a group of patients with nonsmall cell lung cancer (NSCLC) by analyzing their clinical and radiological features. Materials and methods Patients with NSCLC who underwent EGFR mutation detection between 2014 and 2017 were included. Clinical features and general imaging features were collected, and radiomic features were extracted from CT data by 3D Slicer software. Prognostic factors of EGFR mutation status were selected by least absolute shrinkage and selection operator (LASSO) logistic regression analysis, and receiver operating characteristic (ROC) curves were drawn for each prediction model of EGFR mutation. Results A total of 118 patients were enrolled in this study. The smoking index (P = 0.028), pleural retraction (P = 0.041), and three radiomic features were significantly associated with EGFR mutation status. The areas under the ROC curve (AUCs) for prediction models of clinical features, general imaging features, and radiomic features were 0.284, 0.703, and 0.815, respectively, and the AUC for the combined prediction model of the three models was 0.894. Finally, a nomogram was established for individualized EGFR mutation prediction. Conclusions The combination of radiomic features with clinical features and general imaging features can enable discrimination of EGFR mutation status better than the use of any group of features alone. Our study may help develop a noninvasive biomarker to identify EGFR mutation status by using a combination of the three group features.
引用
收藏
页码:271 / 280
页数:10
相关论文
共 50 条
  • [41] Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma
    Shi, Zhang
    Zheng, Xuan
    Shi, Ruifeng
    Song, Changen
    Yang, Runhong
    Zhang, Qianwen
    Wang, Xinrui
    Lu, Jianping
    Yu, Yongwei
    Liu, Qi
    Jiang, Tao
    SCIENTIFIC REPORTS, 2017, 7
  • [42] Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma
    Zhang Shi
    Xuan Zheng
    Ruifeng Shi
    Changen Song
    Runhong Yang
    Qianwen Zhang
    Xinrui Wang
    Jianping Lu
    Yongwei Yu
    Qi Liu
    Tao Jiang
    Scientific Reports, 7
  • [43] Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
    Huang, Chi-Hsien
    Ju, Jia-Shiuan
    Chiu, Tzu-Hsuan
    Huang, Allen Chung-Cheng
    Tung, Pi-Hung
    Wang, Chin-Chou
    Liu, Chien-Ying
    Chung, Fu-Tsai
    Fang, Yueh-Fu
    Guo, Yi-Ke
    Kuo, Chih-Hsi Scott
    Yang, Cheng-Ta
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 626 - 635
  • [44] IMMUNOHISTOCHEMICAL EVALUATION OF E-CADHERIN AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN NONSMALL CELL LUNG-CANCER
    SORSCHER, SM
    RUSSACK, V
    GRAZIANO, S
    CAGLE, M
    FERAMISCO, JR
    GREEN, MR
    MODERN PATHOLOGY, 1995, 8 (04) : 450 - 455
  • [45] Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
    Matsunaga, Takeshi
    Takamochi, Kazuya
    Hattori, Aritoshi
    Fukui, Mariko
    Suzuki, Kenji
    THORACIC AND CARDIOVASCULAR SURGEON, 2023, 71 (08): : 664 - 670
  • [46] Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
    Pirker, Robert
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) : 115 - 121
  • [47] Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun, Jong-Mu
    Park, Keunchil
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 89 - 96
  • [48] Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Sequist, Lecia V.
    Joshi, Victoria A.
    Jaenne, Pasi A.
    Bell, Daphne W.
    Fidias, Pahos
    Lindeman, Neal I.
    Louis, David N.
    Lee, Jeffrey C.
    Mark, Eugene J.
    Longtine, Janina
    Verlander, Peter
    Kucherlapati, Raju
    Meyerson, Matthew
    Haber, Daniel A.
    Johnson, Bruce E.
    Lynch, Thomas J.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4403S - 4408S
  • [49] Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation
    Blons, Helene
    Cote, Jean-Francois
    Le Corre, Delphine
    Riquet, Marc
    Fabre-Guilevin, Elisabeth
    Laurent-Puig, Pierre
    Danel, Claire
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (10) : 1309 - 1315
  • [50] MUTATION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN SQUAMOUS CELL CARCINOMA OF LUNG
    Miwa, Toshiro
    Kashii, Tatsuhiko
    Suzuki, Kensuke
    Yamada, Toni
    Hayashi, Ryuji
    Doki, Yoshinori
    Fukuoka, Junya
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1308 - S1308